Sartorius Stedim Biotech S.A. (SDMHF)
USD 201.5
(0.0%)
USD 201.5
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.77 Billion EUR | -20.53% |
| 2022 | 3.49 Billion EUR | 20.98% |
| 2021 | 2.88 Billion EUR | 51.14% |
| 2020 | 1.91 Billion EUR | 32.59% |
| 2019 | 1.44 Billion EUR | 18.84% |
| 2018 | 1.21 Billion EUR | 12.13% |
| 2017 | 1.08 Billion EUR | 2.8% |
| 2016 | 1.05 Billion EUR | 18.92% |
| 2015 | 884.33 Million EUR | 29.38% |
| 2014 | 683.52 Million EUR | 16.17% |
| 2013 | 588.37 Million EUR | 8.16% |
| 2012 | 543.96 Million EUR | 13.97% |
| 2011 | 477.3 Million EUR | 10.24% |
| 2010 | 432.94 Million EUR | 7.91% |
| 2009 | 401.23 Million EUR | 9.03% |
| 2008 | 367.99 Million EUR | 36.88% |
| 2007 | 268.83 Million EUR | -48.41% |
| 2006 | 521.05 Million EUR | 7.59% |
| 2005 | 484.3 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 706.4 Million EUR | 5.92% |
| 2024 Q1 | 666.9 Million EUR | -5.65% |
| 2024 Q3 | 655.4 Million EUR | -7.22% |
| 2023 Q4 | 706.8 Million EUR | 5.98% |
| 2023 Q3 | 666.9 Million EUR | -1.3% |
| 2023 Q2 | 675.7 Million EUR | -6.94% |
| 2023 Q1 | 726.1 Million EUR | -18.42% |
| 2023 FY | 2.77 Billion EUR | -20.53% |
| 2022 FY | 3.49 Billion EUR | 20.98% |
| 2022 Q4 | 890 Million EUR | 1.32% |
| 2022 Q1 | 862.5 Million EUR | 10.84% |
| 2022 Q3 | 878.4 Million EUR | 1.93% |
| 2022 Q2 | 861.8 Million EUR | -0.08% |
| 2021 Q1 | 655.2 Million EUR | 23.46% |
| 2021 Q2 | 696.7 Million EUR | 6.33% |
| 2021 Q3 | 757 Million EUR | 8.66% |
| 2021 Q4 | 778.17 Million EUR | 2.8% |
| 2021 FY | 2.88 Billion EUR | 51.14% |
| 2020 Q4 | 530.68 Million EUR | 3.97% |
| 2020 Q3 | 510.4 Million EUR | 14.18% |
| 2020 Q2 | 447 Million EUR | 5.9% |
| 2020 Q1 | 422.1 Million EUR | 16.0% |
| 2020 FY | 1.91 Billion EUR | 32.59% |
| 2019 Q3 | 367.4 Million EUR | 0.27% |
| 2019 Q4 | 363.87 Million EUR | -0.96% |
| 2019 FY | 1.44 Billion EUR | 18.84% |
| 2019 Q2 | 366.4 Million EUR | 6.85% |
| 2019 Q1 | 342.9 Million EUR | 8.49% |
| 2018 Q2 | 304.6 Million EUR | 8.36% |
| 2018 Q1 | 281.1 Million EUR | 1.73% |
| 2018 FY | 1.21 Billion EUR | 12.13% |
| 2018 Q4 | 316.05 Million EUR | 1.82% |
| 2018 Q3 | 310.4 Million EUR | 1.9% |
| 2017 Q2 | 277.9 Million EUR | 3.39% |
| 2017 FY | 1.08 Billion EUR | 2.8% |
| 2017 Q4 | 276.33 Million EUR | 6.73% |
| 2017 Q3 | 258.9 Million EUR | -6.84% |
| 2017 Q1 | 268.8 Million EUR | 0.86% |
| 2016 Q1 | 245.8 Million EUR | 10.01% |
| 2016 Q4 | 266.51 Million EUR | -3.54% |
| 2016 FY | 1.05 Billion EUR | 18.92% |
| 2016 Q3 | 276.3 Million EUR | 5.06% |
| 2016 Q2 | 263 Million EUR | 7.0% |
| 2015 Q4 | 223.43 Million EUR | -6.48% |
| 2015 Q1 | 204.4 Million EUR | 8.02% |
| 2015 Q2 | 217.6 Million EUR | 6.46% |
| 2015 FY | 884.33 Million EUR | 29.38% |
| 2015 Q3 | 238.9 Million EUR | 9.79% |
| 2014 Q4 | 189.22 Million EUR | 11.24% |
| 2014 Q2 | 170.2 Million EUR | 10.52% |
| 2014 Q3 | 170.1 Million EUR | -0.06% |
| 2014 FY | 683.52 Million EUR | 16.17% |
| 2014 Q1 | 154 Million EUR | 1.46% |
| 2013 Q2 | 154.6 Million EUR | 0.0% |
| 2013 Q4 | 151.77 Million EUR | 5.4% |
| 2013 Q3 | 144 Million EUR | -6.86% |
| 2013 FY | 588.37 Million EUR | 8.16% |
| 2012 FY | 543.96 Million EUR | 13.97% |
| 2012 Q2 | 139.1 Million EUR | 0.0% |
| 2011 Q2 | 118.8 Million EUR | 0.0% |
| 2011 FY | 477.3 Million EUR | 10.24% |
| 2010 FY | 432.94 Million EUR | 7.91% |
| 2010 Q2 | 109.1 Million EUR | 0.0% |
| 2009 FY | 401.23 Million EUR | 9.03% |
| 2008 FY | 367.99 Million EUR | 36.88% |
| 2007 FY | 268.83 Million EUR | -48.41% |
| 2006 FY | 521.05 Million EUR | 7.59% |
| 2005 FY | 484.3 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| American Medical Technologies Inc. | 3.19 Million USD | -86866.085% |
| Ansell Limited | 1.61 Billion USD | -71.401% |
| Ansell Limited | 1.61 Billion USD | -71.401% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 184.64 Million USD | -1403.134% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 135.05 Thousand USD | -2054988.668% |
| Psykey, Inc. | 419.29 Thousand USD | -661838.14% |
| ConvaTec Group Plc | 2.19 Billion USD | -26.503% |
| ConvaTec Group Plc | 2.14 Billion USD | -29.551% |
| Encision Inc. | 6.58 Million USD | -42043.178% |
| Golden Valley Development, Inc | - USD | -Infinity% |
| Hear AtLast Holdings, Inc. | - USD | -Infinity% |
| Innovative MedTech Inc. | 1.82 Million USD | -151988.442% |
| LifePoint, Inc. | -18.5 Thousand USD | 15002802.703% |
| Medite Cancer Diagnostics, Inc. | 6.81 Million USD | -40638.294% |
| Paradigm Medical Industries, Inc. | 772 Thousand USD | -359420.725% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | 986.22 Thousand USD | -281328.079% |
| Reflect Scientific, Inc. | 1.08 Million USD | -256854.101% |
| SmileDirectClub, Inc. | 470.74 Million USD | -489.6% |
| Sector 10, Inc. | - USD | -Infinity% |
| Shandong Weigao Group Medical Polymer Company Limited | 1.87 Billion USD | -48.295% |
| SheerVision, Inc. | 3.49 Million USD | -79213.438% |
| United Health Products, Inc. | - USD | -Infinity% |
| Vasamed, Inc. | 1.38 Million USD | -200110.056% |
| Wearable Health Solutions, Inc. | 745.09 Thousand USD | -372403.835% |
| Yubo International Biotech Limited | 104.28 Thousand USD | -2661407.628% |